Genmab — Maj 2021

[E_L]

lol, no that is still the one from last year , 2020

[E_L]

EHA poster SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA: SAFETY PROFILE AND ANTI-TUMOR ACTIVITY https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/325259/rogier.mous.subcutaneous.epcoritamab.in.patients.with.relapsed.refractory.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Depcoritamab

[E_L]

DARATUMUMAB MAINTENANCE VS OBSERVATION, finaly - Conclusion
CASSIOPEIA part 2 interim analysis showed a significantly longer PFS with daratumumab maintenance vs OBS in transplant-eligible patients with NDMM. https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/324588/philippe.moreau.daratumumab.maintenance.vs.observation.in.patients.with.newly.html?f=listing%3D1*browseby%3D8*sortby%3D2*media%3D3*ce_id%3D2035*label%3D21988*ot_id%3D25572*search%3Ddaratumumab*marker%3D1285

[Bulder]

thx E L. What do you think of epco? Efficacy looks similar to glofitamab, but AE looks better. Best in class?

[Bulder]

Just a moment...

(www.onclive.com)

[GeorgeBest]

If you only look at patients receiving optimal dose of Epcoritamab (48 mg), isn’t the Epcoritamab data better then?

[Bulder]

Maybritt a little. But is it enough to be meaningfull?

[Bulder]

NBI opfører sig da noget pænere end øvrige us-inden.

[Bulder]

Inden

[Bulder]

Index

[Bulder]

Forpulede iPad

[Bulder]

... relativt

[Bulder]

Ipad er absolut forpulet. NBI er relativt velopdragen i dag.

[Bulder]

Jeg tror jeg fandt ud af at slå automatiske rettelser fra.

[Bulder]

Ret voldsomt ellers i us her i aften. De næste to dage bliver spændende. Hvis det fortsætter, så bliver det ikke morsomt på mandag.

[Bulder]

Den ene fed’er efter den anden er ude at slå koldt vand i blodet. Håber det trænger ind.

[Helge_LarsenPI-redaktør]

God morgen.

[Helge_LarsenPI-redaktør]

Spørgsmål til Q&A er meget savnet.

[E_L]

@Bulder , If I look at comparison with earlier epcoritamab data, for the higher dose;

[E_L]

For DLBCL ≥48 mg (n=11); ORR 91% (CR=55%; PR=36%) versus november data: (n=7); ORR 100% (CR=28.6%; PR=71.4%)